82VS — Full Portfolio
9 tracked investments · listed companies and verified rows first
Aakha Bio develops multi-specific antibodies for solid tumors that block disease pathways and activate immune cells.
BiotechHealthtechMedical DevicesFrisco, US
Hemanta Baruah(Founder & CEO)in
BoardErrik Anderson(Director)inChristopher Pacheco(Director)George Robert Mabry III(Director)
Alloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
AI & Machine LearningBiotechDeep TechHealthtechWaltham, US
Tillman Gerngross(Founder, CEO, Chairman)
Co-investors8VCCalm VenturesGermin8 Ventures
A venture studio embedded within Alloy Therapeutics that partners with academics, entrepreneurs, pharma companies, and VCs to create and develop early-stage drug discovery companies.
BiotechDeep TechWaltham, US
Errik B. Anderson(Executive Officer, Director)inPiotr Bobrowicz(Executive Officer, Director)inJay Rosanelli(Executive Officer)in
BoardAnthony Sun(Director)Alaa Halawa(Director)Ulrik Nielsen(Director)in
Co-investors8VCJIC Venture Growth InvestmentsMC Healthcare VenturesMission Biocapital
Cantai develops rationally designed bispecific antibodies that combine clinically validated mechanisms to treat patients with autoimmune disease.
BiotechHealthtechPhiladelpia, US
Errik Anderson(Executive Officer, Director)inRoss Leimberg(Executive Officer, Director)in
BoardJoshua Brandt(Director)Geeta Vemuri(Executive Officer, Director)in
Co-investorsAgent Capital
Overture develops precision antibody therapeutics for obesity treatment, targeting metabolic dysfunction pathways to reduce fat mass while preserving lean muscle through monthly-dosed therapeutic approaches.
BiotechHealthtechMedical Devices
Voro Therapeutics develops tumor-activated biologics, specifically an antibody-based platform called PrimeBody™, designed to treat cancers including colorectal, gastric, prostate, and lung cancers while minimizing systemic toxicity.
BiotechMedical DevicesSan Diego, US
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AldebarantxYpsilon Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.